Recent updates in applications of nanomedicine for the treatment of hepatic fibrosis

• Damai Ria Setyawati,
• Fransiska Christydira Sekaringtyas,
• Riyona Desvy Pratiwi,
• A’liyatur Rosyidah,
• Rohimmahtunnissa Azhar,
• Nunik Gustini,
• Gita Syahputra,
• Idah Rosidah,
• Etik Mardliyati,
• Tarwadi and
• Sjaikhurrizal El Muttaqien

Beilstein J. Nanotechnol. 2024, 15, 1105–1116, doi:10.3762/bjnano.15.89

• enormous technological success also included various other target diseases, including hepatic fibrosis. This confirms the versatility of nanomedicine for improving therapeutic activity. In this review, we summarize recent updates of nanomedicine platforms for improving therapeutic efficacy regarding liver

• targeting; hepatic fibrosis; nanocarriers; nanomedicine; passive targeting; Introduction Over the last three decades, we have witnessed tremendous progress in the field of nanomedicine through the preparation of a vast number of nanoscale (bio)materials. Nanomedicine itself is defined as the biomedical

• agents in a single nanocarrier has been a primary goal particularly for nanomedicine-based cancer immunotherapy, allowing for both suppression of tumor growth and inhibition of metastatic spread. Recent research trends on active targeting strategies for hepatic fibrosis still focus on exploiting HSCs as